An aggressive malignant peripheral nerve sheath tumor of an atypical site such as the scalp, in which complete surgery may not always be possible, could benefit from postoperative radiotherapy. A dose of approximately 60 Gy could be effectively delivered with a satisfactory outcome.

Background: Aneurysmal bone cysts are relatively uncommon in the facial skeleton. These usually affect the mandible but origin from the coronoid process is even rarer. To the best of our knowledge, this is the first reported case of a coronoid process aneurysmal bone cyst presenting as temporal fossa swelling.

BACKGROUNDFine needle aspiration cytology is known to have a well-established role in the diagnosis and management of palpable breast lumps. Breast carcinoma is the second most common cause of death in female patients, male breast carcinoma is rare, accounting for less than 1% of all breast cancers and all cancers in men. Male breast masses are rarely aspirated and hence there is limited cytopathological experience.The aim of our study is to determine the efficacy of FNAC in the diagnosis of male breast lesions.

treatment for locally advanced or metastatic disease, history of leptomeningeal disease, interstitial lung disease, and prior treatment with an EGFR TKI. Approximately 1000 patients will be randomly assigned 2:2:1 to receive amivantamab + lazertinib (nw400), osimertinib (nw400), or lazertinib (nw200). Randomization will be stratified by mutation type (Exon19del vs L858R), race (Asian vs non-Asian), and history of brain metastases (present vs absent). Patients in the combination arm will receive open-label treatment with amivantamab (1050 mg [1400 mg, patients 80 kg] intravenously once weekly for the first 4 weeks, every 2 weeks thereafter) + lazertinib (240 mg oral daily). Patients in the single-agent osimertinib and lazertinib arms will receive double-blind treatment (80 mg or 240 mg oral daily, respectively). The primary endpoint of the study is progression-free survival (PFS) based on blinded independent central review according to RECIST v1.1. To assess the contribution of amivantamab to the efficacy of the combination, comparison of the combination and monotherapy lazertinib arms will also be performed. Secondary endpoints include overall survival, objective response rate, duration of response, PFS after first subsequent therapy, time to symptomatic progression, and intracranial PFS. Safety assessments will include monitoring adverse events and laboratory abnormalities.

Background The expanding clinical indications of cardiac rhythm management have led to an increased use of pacemaker implantation which is associated with increased incidence of pacemaker infections. Staphylococcus aureus and epidermidis account for the vast majority of pacemaker infections. Pacemaker infection due to Mycobacterium tuberculosis (M. tuberculosis) is very rare, only few cases having been reported till date.MethodsWe describe here a study of three patients of pacemaker pocket infection with M. tuberculosis.ConclusionThe possibility of mycobacterial pacemaker infection should always be kept in mind in patients with delayed pacemaker infection.

Few studies have been performed to evaluate the p53 protein expression in gallbladder carcinoma and its relationship to histopathological grade of the tumor. Based on these facts the aim of our study was to assess the p53 overexpression in correlation to the grade of tumor. Material and Methods: 80 cases of histologically proven gall bladder carcinoma were included in the study.p53 immunostaining was done and score was calculated. Results: It was observed that out of 80 cases of gall bladder malignancy, 30(37.5%) cases were p53 positive and 50(62.5%) were p53 negative. There was statistically significant difference between the histological grade of p53 positive and p53 negative adenocarcinomas with significantly higher number of patients of p53 overexpression presenting with poorly differentiated adenocarcinomas. Conclusion: p53 overexpression has inverse relationship with the grade of the tumor.

The oral cavity mucosal tissue alteration can manifest in a variety of lesions where great majority of localized overgrowths of the oral mucosa are considered to be reactive rather than neoplastic in nature. Many of these lesions can be identified as specific entities on the basis of their histopathological features. In our present study, we have evaluated the various benign lesions of oral cavity with emphasis on relative frequencies, types and distribution of lesions. MATERIALS AND METHODSAll the benign lesions of oral cavity diagnosed by histopathology in the Department of Pathology, K. S. Hegde Medical Academy of Nitte University over a period of two years from July 2012 to June 2014 were retrospectively studied. Paraffin tissue blocks were collected from Histopathology Department and 5 microns thick. Sections stained with Hematoxylin and Eosin were studied by histopathologist. RESULTSA total of 124 cases were analyzed during the study period. The age group ranged from 8 to 86 years in the study with a mean age of 63.9 years. Buccal mucosa was the most common site involved in 44(35.5%) cases. Benign lesions of oral cavity included inflammatory/infective lesions in 30(24.2%) cases, traumatic/hyperplastic in 30(24.2%), cystic in 10(8%) developmental lesions in 16(13%), pre-malignant lesions comprising of leukoplakia and erythroplakia in 20(16%) and benign neoplastic lesions constituted in 18(14.6%) cases. Leukoplakias are the common benign lesions of the oral cavity followed by hemangiomas, hyperplasia and squamous papilloma. In the buccal mucosa, most common lesions were leukoplakia and lichen planus. CONCLUSIONThe increased frequency of benign neoplastic lesions (14.6%) in our study and less (4%) as compared to other author is possibly due to limited sample size in ours as contrast to large population based study by them.

Background: The intrauterine device (IUD) is the most commonly used reversible family planning method all over the world .The risk of cervical neoplasia associated with use of an intrauterine device (IUD), specially the copper releasing one, has been an important concern. The aim and objectives of the study was to determine safety of copper IUCD with regard to changes in cervical cytology and to compare the changes with other methods of temporary contraception. Methods: This was a prospective study carried out at a tertiary care institute for a period of 3 years. A total of 200 women of age group 18-40 years were included. 100 subjects who opted CuT 380A IUD were compared with 100 controls that had either opted other mode of temporary contraception like barrier, injectable, oral or did not use any method. Detailed history and examination of all subjects were done. All the women were subjected to conventional Pap smear and were followed at 6 months of interval for 1 year and then yearly up to 3 years. In each visit thorough pelvic examination was done and PAP smears were taken. Results: Among women using IUCD, 67.7% showed normal cytology as compared to 72.0% of the controls. On follow up, the incidence of normal cytology decreased (40%) with increased duration of use (up to 3 years). Incidence of inflammatory smear though first decreased up to 1 year (21.8%) but then gradually increased up to 2 years (37.0%) of use and then again decreased to 20.0% up to 3 years of use. ASCUS was found in only one case that used the device up to 2 years of use. LSIL was detected in 2 cases (20%) using IUD up to 3 years. No case of high grade intraepithelial lesion (HSIL) or invasive cancer was seen. Conclusions: There was no significant risk of cervical dysplasia or invasive carcinoma in IUCD users up to 2 years of use while other contraceptives (except barrier one) showed increased incidence of mild dysplasia (LSIL) after 1 year of use. Though risk of cervical malignancy is less with intrauterine copper devices, regular follow up should be done in long term users.